论文部分内容阅读
目的比较奥沙利铂联合5-Fu/LV或羟基喜树碱联合5-Fu/LV对进展期胃癌根治切除后辅助化疗的疗效。方法79例III期胃癌根治切除后患者接受治疗,其中Oxaliplatin+5-Fu/LV方案(奥沙利铂组)40例,HCPT+5-Fu/LV方案(羟基喜树碱组)39例,病人一般特征经χ2检验,两组具有可比性(P>0.05)。结果奥沙利铂组三年生存率87.5%,羟基喜树碱组三年生存率69.2%,两组三年生存率差异有显著性(P<0.05)。毒副反应两组Ⅰ~II外周神经毒性有显著性差异,Oxaliplatin组为62.9%,HCPT组为31.6%(P<0.05),其他毒副反应的差异无显著性(P>0.05)。结论奥沙利铂联合5-Fu/LV对III期胃癌术后辅助化疗效果确切,毒副反应可耐受,不失为进展期胃癌根治切除后辅助化疗的较好选择。
Objective To compare the efficacy of oxaliplatin combined with 5-Fu/LV or hydroxycamptothecine combined with 5-Fu/LV for adjuvant chemotherapy after radical resection of advanced gastric cancer. Methods Seventy-nine patients with radical resection of stage III gastric cancer were treated with Oxaliplatin+5-Fu/LV regimen (Oxaliplatin group) and HCPT+5-Fu/LV regimen (hydroxycamptothecin group, 39 cases). The general characteristics of patients were examined by χ2 test. The two groups were comparable (P>0.05). Results The three-year survival rate was 87.5% in the oxaliplatin group and 69.2% in the hydroxycamptothecin group. The three-year survival rate was significantly different between the two groups (P<0.05). Peripheral neurotoxicity was significantly different between the two groups, with 62.9% in Oxaliplatin group and 31.6% in HCPT group (P<0.05). There was no significant difference in other toxicities (P>0.05). Conclusion Oxaliplatin combined with 5-Fu/LV has a definite effect on postoperative adjuvant chemotherapy for stage III gastric cancer, toxic and side effects can be tolerated, and is a good choice for adjuvant chemotherapy after radical resection of advanced gastric cancer.